| First Author | Snellman A | Year | 2017 |
| Journal | Neurobiol Aging | Volume | 57 |
| Pages | 84-94 | PubMed ID | 28605642 |
| Mgi Jnum | J:249742 | Mgi Id | MGI:6092761 |
| Doi | 10.1016/j.neurobiolaging.2017.05.008 | Citation | Snellman A, et al. (2017) Applicability of [(11)C]PIB micro-PET imaging for in vivo follow-up of anti-amyloid treatment effects in APP23 mouse model. Neurobiol Aging 57:84-94 |
| abstractText | In this study, we evaluated the anti-amyloid effect of functionalized nanoliposomes (mApoE-PA-LIP) in a mouse model of Alzheimer's disease with use of positron emission tomography and beta-amyloid (Abeta)-targeted tracer [(11)C]Pittsburgh compound B ([(11)C]PIB). APP23 mice were injected with mApoE-PA-LIP or saline (3 times per week for 3 weeks) and [(11)C]PIB imaging was performed at baseline, after the treatment and after 3 months follow-up period, accompanied by Abeta immunohistochemistry and ELISA. After the treatment, [(11)C]PIB binding ratios between mApoE-PA-LIP and saline groups were equivalent in all analyzed brain regions; however, in the saline group, binding ratios increased from the baseline, whereas no increase was detected in the mApoE-PA-LIP group. During the additional follow-up, [(11)C]PIB binding increased significantly from baseline in both groups, and binding ratios correlated with the immunohistochemically defined Abeta load. This study further supports the use of [(11)C]PIB positron emission tomography imaging as a biomarker of Abeta deposition in APP23 mice and highlights the benefits of noninvasive follow-up, that is, using baseline data for animal stratification and normalization of treatment effects to baseline values, for future anti-amyloid treatment studies. |
